Retinal degeneration and protection

New strategies for neuroprotection in glaucoma, a disease that affects the central nervous system

Carlo Nucci a,⁎, Rossella Russo b,c, Alessio Martucci a, Clarissa Giannini a, Francesco Garaci d,e, Roberto Floris d, Giaicinto Bagetta b,c, Luigi Antonio Morrone b,c

a Ophthalmology Unit, Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome Italy
b Department of Pharmacy, Nutritional and Health Sciences University of Calabria, Arcavacata di Rende, Italy
c University Center for Adaptive Disorders and Head Pain, Section of Neopharmacology of Normal and Pathological Neuronal Plasticity, University of Calabria, Arcavacata di Rende, Italy
d UOC Neuroradiologia, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Italy
e San Raffaele Cassino (FR), Italy

⁎ Corresponding author.
E-mail address: nucci@med.uniroma2.it (C. Nucci).

Article history:
Received 29 December 2015
Received in revised form 23 March 2016
Accepted 14 April 2016
Available online 16 April 2016

Keywords:
Glaucoma
Neuroprotection
Retinal ganglion cell
Optic nerve
Intraocular pressure

1. Introduction

Glaucoma is currently recognized to be a multifactorial, progressive, neurodegenerative disorder characterized by the death of retinal ganglion cells (RGCs) associated to the loss of axons that make up the optic nerve. These ultrastructural alterations progressivelly evolve and clinically manifest with increased excavation of the optic disc and consequent specific and irreversible visual field (VF) defects resulting in visual disability and altered quality of life (Cesareo et al., 2015a). With more than 60 million people affected, glaucoma is actually recognized the leading cause of irreversible blindness worldwide (see Cedrone et al., 2008, 2012; Nucci et al., 2005a).

Several clinical studies demonstrated that increased intraocular pressure (IOP), over the levels considered physiological, is the main risk factor for the onset and progression of neuronal damage. In particular, the Collaborative Normal-Tension Glaucoma Study (CNTGS) endorsed the hypothesis that IOP reduction could prevent visual field deterioration. (Group CN-TGS, 1998a, 1998b) Concordantly, the Ocular Hypertensive Treatment Study (Kass et al., 2002) and the Early Manifest Glaucoma Trial (Heijl et al., 2002), respectively, showed that reducing the IOP by using ocular medications is effective in preventing the onset or delaying the progression of the disease. In accordance to these data, glaucoma therapy is currently based on IOP reduction by medical, surgical or parasurgical treatments. However, there is a percentage of patients that experience disease progression, despite their IOP values do not differ from the normal range or are satisfactorily controlled by therapy (Leske et al., 2003). In this regard, it has been suggested that RGCs death is not related to an absolute IOP value but is linked to individual susceptibility (Osborne et al., 2006).

Therefore, despite the IOP represents a risk factor widely documented, glaucoma researcher are trying to develop IOP independent treatments for the disease based on neuroprotection (Regine et al., 2006; Kersey et al., 2013). The need of neuroprotective treatments for glaucoma is also supported by two recently investigated aspect of glaucoma disease: the involvement of the central area of the visual system and the links with neurodegenerative diseases of the central nervous system.

2. Brain involvement in glaucoma: MRI studies

Glaucoma is a progressive disease characterized by apoptosis of the RGCs, which are considered an extension of the central
nervous system (CNS). It is now believed that neuronal degeneration in glaucoma is not limited to the eye but also extends, triggered by different molecular pathways, to the central visual areas, affecting the lateral geniculate nucleus, the visual cortex and the afferent pathway (Nucci et al., 2003, 2013a; Martucci et al., 2014). In particular, the atrophy of neurons in the lateral geniculate nucleus and the visual cortex has been documented in primates with experimental glaucoma (Yücel et al., 2000, 2003; Weber et al., 2000). The involvement of the CNS was also described in humans with glaucoma, ex vivo, by Chattervedi et al. (1993) and then confirmed, both histologically and using magnetic resonance, by Gupta et al. (2006, 2009) and by Dai et al. (2011). In this regard, our group using Magnetic Resonance Imaging (MRI) with diffusion tensor (DT-MRI) confirmed that patients with glaucoma show alterations not only of the optic nerve, but also of the optic radiations (Garaci et al., 2009). DT-MRI parameters at the level of the optic nerve showed a good correlation not only with the progression of the disease, but also with morphological features of the optic nerve head and the retinal nerve fiber layer (RNFL) thickness assessed by GDX-VCC, Heidelberg Retinal Tomography III and Stratus Optical Coherence Tomography (Nucci et al., 2012). Moreover, DT-MRI parameters analysis showed a different pattern of diffusion of the disease that in early glaucoma the neuronal damage resulted predominantly located in the proximal portions of the optic nerve, at the level of retro-laminar region, while in the advanced stages both the proximal and distal portions of the nerves were affected (Bolacchi et al., 2012).

Although conventional neuroimaging still plays an important role, advanced MR techniques, such as diffusion tensor imaging, functional imaging, and magnetic resonance spectroscopy, allow to identify in vivo and noninvasively changes along the visual pathway in both early and late stages of the disease (Garaci et al., 2015; Mastropasqua et al., 2015). In this regard, a recent study using multimodal MRI and whole-brain explorative voxelwise analyses, showed the occurrence, in patients with advanced glaucoma, of structural and functional changes not limited to the white matter tracts of the visual pathway, but also extended to nonvisual areas of the central nervous system, such as superior longitudinal fascicle, anterior thalamic radiations, corticospinal tract, middle cerebellar peduncle, frontoparietal cortex, hippocampus and cerebellar cortex (Frezzotti et al., 2014).

3. Glaucoma and Neurodegenerative diseases

Glaucoma is a complex neurodegenerative disease whose pathogenesis is still not entirely known.

Recent evidence reports that some of the cases we actually define as glaucoma may be the expression of neurodegenerative or vascular diseases of the central nervous system only partially or even completely unaffected by ocular risk factors (Nucci et al., 2015; Danesh-Meyer and Levin, 2015).

Epidemiological studies reported numerous evidences of increased prevalence of glaucoma in patients affected by Alzheimer Disease (AD). In this regard, Bayer et al. (2002a) firstly revealed that 24.5% of AD patients had possible diagnosis of glaucoma compared to the 6.5% of control and then confirmed, in another study, an occurrence rate of glaucoma in the 25.9% of AD patients compared to the 5.2% of matched controls (Bayer et al., 2002b). Likewise, Tamura et al. (2006) described a 23.8% prevalence of primary open angle glaucoma in AD patients with respect of the 9.9% of the controls. In accordance, Cesareo et al. (2015b) showed that the frequency of glaucoma-like alterations was four times higher (27.5%) in AD patients than that of controls (7.5%). Interestingly, in these studies intraocular pressure values were not statistically different between groups, thus suggesting that AD subjects may be more vulnerable to develop clinical pictures similar to those found in glaucoma even if exposed to IOP levels considered in the normal range.

Pelletier et al. (2014), recently confirmed these results showing a higher prevalence of glaucoma in adults with dementia of the Alzheimer's type or dementia with vascular contribution when compared to controls.

In agreement with the epidemiological data, recent studies showed the presence of altered biomarkers of AD, such as amyloid-β, tau, and phosphorylated tau in animals with experimental glaucoma or in affected patients, supporting the hypothesis of a common pathogenesis between the diseases (Guo et al., 2007; Gupta et al., 2008; Inoue et al., 2013; Nucci et al., 2011, 2015). Moreover, Wostyn et al. (2008) hypothesized that the cerebrospinal fluid pressure (CSFP) may be responsible for the greater risk of glaucoma reported in patients with AD. In fact, it has been suggested that in glaucoma an imbalance between the CSFP and the IOP over the lamina cribrosa, caused by reduced levels of CSFP, may cause a displacement of the fibers damaging the RGCs. Interestingly, reduced CSFP has been observed in a small percentage of patients with AD (Silverberg et al., 2006). In addition, Killi et al. (2008a) hypothesized that due to altered CSF circulatory dynamics and being surrounded by CSF contained in the subarachnoid space, the optic nerve, might be exposed, to the neurotoxic molecules released by Alzheimer's disease, such as β-amyloid- and tau, with a cytotoxic effect (Killi et al., 2008a, 2008b; Wostyn et al., 2013).

Finally, the reduction of beclin 1, a gene product involved in the autophagy machinery, has been recently proposed as a potential contributing factor in neurodegenerative diseases, such as AD. Accordingly, recent studies show that autophagy constitutively takes place in RGC and acute IOP elevation, causes autophagy derangement and RGC death (Jaeger and Wyss-Coray, 2009; Rodrigo-Muela and Boya, 2012; Russo et al., 2011, 2013a), thus suggesting that in both diseases there may be an alteration of the autophagic pathway.

As for AD there is evidence of a possible connection between Parkinson Disease (PD) and glaucoma. In particular, Bayer et al. (2002a) and Nowacka et al. (2014) reported a higher incidence of glaucoma in PD. Interestingly, in these studies PD patients had normal or significantly lower IOP values compared to controls. This data was also confirmed by Venice et al. (2008) and Tzironi et al. (2012), which reported a higher prevalence of glaucomatous visual field defects in patients with PD. These alterations have been subsequently corroborated by several studies reporting a significantly reduced RNFL thickness in patients with PD (Inzelberg et al., 2004; Altintas et al., 2008; Eraslan et al., 2015).

Another possible connection has been suggested between Leber Hereditary Optic Neuropathy (LHON) and glaucoma (Nucci et al., 2013b; Thouin et al., 2013). In this regard, optic nerve head cupping (Mashima et al., 2003; Inagaki et al., 2006) and delayed VF loss (Newman, 1993) have been described in people carrying mtDNA mutation. This suggests that raised IOP could be a risk factor for visual loss in carriers of LHON mutations.

Interestingly, several reports suggested a possible connection also between glaucomatous damage and cerebrovascular alterations. In particular, drops in regional cerebral blood flow, especially in those areas of the visual system situated in watershed areas, may induce infarctions that lead to axonal and glial degeneration, as well as to the development of the typical alterations of glaucoma (Pantoni and Garcia, 1997; Momjian-Mayor et al., 2005; Leung et al., 2009). Hence, the vascular alterations, which are IOP independent, and the resulting ischemic phenomena, may induce and/or synergize with the glaucomatous degenerative process.
4. Glaucoma and neuroprotection

Overall, these data support the hypothesis that glaucomatous damage is not limited to the eye, but it also involves the central visual pathways. These alterations may be either the consequence of the anterograde transynaptic diffusion of death signals prompted by the RGCs, or the result of a retrograde mechanism of transduction induced by neurodegenerative diseases that primarily affect the CNS (Nucci et al., 2013a). In view of this, pharmacological treatments targeting IOP may not be sufficient to control the disease, thus indicating the need of novel neuroprotective strategies aimed to prevent, slow down or stop the RGC loss.

Several animal models are available to reproduce the apoptotic death of RGCs and to test the neuroprotective potential of drugs. The models differ regarding the type of applied insult that varies from short to medium-term elevation of IOP, to axonal injury (e.g. crushing or resection of the optic nerve) and induction of retinal hypoxia/ischemia (see Johnson and Tomarev, 2010). It has to be stressed that none of them entirely recapitulate the features of glaucoma neurodegeneration and therefore drugs showing neuroprotective properties should be tested in more than one model in order to validate the translational value of the data.

The hostile environment that leads to glaucoma-associated death of RGCs following a still undetermined trigger, is characterized by alteration of several pathways including neurotrophin signaling, oxidative stress, excitotoxicity, mitochondrial dysfunction, protein misfolding, ischemic events, autoimmunity and neuroinflammation (Baltmik et al., 2010). Therefore, each of these components might represent a potential target for achieving neuroprotection.

4.1. Anti-excitotoxicity strategies

Several studies suggested that excitotoxicity plays a key role in RGC degeneration associated with glaucoma through the over-activation of both N-methyl-D-aspartate (NMDA) and non-NMDA glutamate receptors (Nucci et al., 2005b; Russo et al., 2009). Indeed, despite the doubts that have been raised regarding the effective role of glutamate in glaucoma (see Salt and Cordeiro, 2006), several authors reported neuroprotection following treatment with MDMA and non-NMDA antagonists in experimental models of RGC death (Sucher et al., 1997; Adachi et al., 1998; Nucci et al., 2005b). Accordingly, blocking NO synthase (ROS), an enzyme involved in the excitotoxic cascade, by systemic pretreatment with the non-selective inhibitor L-NAME, minimized RGC loss (Nucci et al., 2005b).

Quite interestingly, modulation of the Akt pathway seems to be implicated in the neuroprotection afforded by NMDA receptor blockade (Russo et al., 2011).

Although the literature reports conflicting data (Dreyer et al., 1996; Brooks et al., 1997; Levkovitch-Verbin et al., 2002; Carter-Dawson et al., 2002; Honkanen et al., 2003; Wamsley et al., 2005), increased vitreal glutamate concentrations have been demonstrated in experimental models of glaucoma (Louzada-Júnior et al., 1992; Adachi et al., 1998; Nucci et al., 2005b) and this can be associated with excitatory amino acid transporters (EAAT) dysfunction (Martin et al., 2002; Russo et al., 2013b).

Under acute retinal ischemia, the glial glutamate-aspartate transporter (GLAST) showed a reduced efficiency leading to extracellular glutamate accumulation (Barnett et al., 2001) and Naskar et al. (2000) reported a reduction of GLAST expression in glaucomatous eyes. Vice versa, no significant change in GLAST expression was observed after optic nerve transection (Martin et al., 2002). Recently, using isolated retinal synaptosomes, our group reported changes in neuronal glutamate transporter subtype 1 (GLT-1) but not GLAST expression after retinal ischemia/reperfusion (Russo et al., 2013b) supporting a role for neuronal transporters in these phenomena. Moreover, our results suggested the presence of an alternative, neuronal splice variant of GLT-1, induced in response to the ischemic damage (Russo et al., 2013b).

The potential involvement of the excitotoxic cascade in glaucoma-associated RGC death has prompted researchers to test the neuroprotective potential of drugs targeting this pathway.

4.1.1. Neuroprotectants

Since the 2000s several authors have shown neuroprotective effects on RGCs following treatment with memantine, an use-dependent blocker of the NMDA channel approved in Europe and USA for the treatment of Alzheimer’s dementia. Gu et al. (2000) reported its ability to reduce RGC loss in rat after laser trabecular photocoagulation, and Hare et al. (2001) observed protective effects on visually-evoked cortical potential amplitude in monkey and RGC survival in rat. Likewise, WoldeMussie et al. (2002) reported memantine neuroprotection after optic nerve injury and in a chronic ocular hypertension model in rat. Further studies carried out by Hare et al. (2004a, 2004b) in primates confirmed the efficacy and safety of memantine. Lipton theorized that memantine could be a promising neuroprotective agent for the treatment of glaucoma since it preferentially blocks excessive NMDA receptor activity without interfering with normal synaptic transmission (Lipton, 2003, 2004). However, despite the positive results obtained from preclinical studies (Zhong et al., 2007; Hare and Wheeler, 2009; Ju et al., 2009), the clinical trial did not completely support the potential beneficial effects of the NMDA antagonist (see Sena and Lindsley, 2013).

Other compounds have shown neuroprotective properties in experimental models of glaucoma by interfering with excitotoxic mechanisms.

Brimonidine is an α2 adrenergic agonist clinically used for the treatment of glaucoma due to its ability of lowering IOP. Wheeler et al. (2003) have shown that treatment with brimonidine is associated with neuroprotective effects on RGCs loss in different experimental models of glaucoma. Accordingly, work by Villena et al. (2009) and Vidal et al. (2010) supported the retinal neuroprotective effect of brimonidine. In particular, Vidal et al. (2010) have shown that hypotensive drugs attenuate retinal gliosis. More recently, Jung et al. (2015) reported that brimonidine decreases RGC apoptosis upregulating EAAT1 and downregulating NMDA receptors.

Our group reported RGC neuroprotection elicited by 17β-estradiol in experimental retinal ischemia induced by transient increase of IOP (Russo et al., 2008b); the observed neuroprotection is associated with decreased vitreal glutamate levels and this might be the event preventing RGC death (Russo et al., 2008a). Accordingly, increased glutamate uptake prevents the death of RGCs (Pawlak et al., 2005).

Recently, Sakamoto et al. (2015) reported that P2 × 7 receptor antagonists protect against NMDA-induced retinal injury in rat decreasing the number of terminal deoxynucleotidyl transferase dUTP nick end labeling-positive (TUNEL) cells. Moreover, Yagisawa et al. (2015) reported that arundic acid, a glial modulating agent, reduces RGC death by increasing GLAST expression in a model of normal tension glaucoma. Furthermore, valproic acid, a drug widely prescribed for treatment of epilepsy, mood disorders, migraines, and neuropathic pain, shows protective effects and reduced RGC death induced by NMDA intravitreal injection likely stimulating brain-derived neurotrophic factor up-regulation in Müller glial cells (Kimura et al., 2015).

Neuropeptide Y receptors activation also protects retinal cells against excitotoxicity in rat by the activation of protein kinase A and p38K (Santos-Carvalho et al., 2013). Y2 and Y4 receptors are...
involved in the protective effect of neuropeptide Y against necrotic, while Y5 against necrotic and apoptotic cell death induced by glutamate (Santos-Carvalho et al., 2013).

Interestingly, in 2012, Froger and colleagues reported a protective effect of the amino acid taurine against excitotoxicity showing increase RGC survival in vivo and in vitro and suggesting that enriched taurine nutrition can directly promote RGC survival (Froger et al., 2012). Moreover, nafamostat mesilate, a serine protease inhibitor showed protection against NMDA-induced neuronal and vascular damage in rat retinas (Tsuda et al., 2012).

4.1.2. Antioxidant agents

Oxidative stress, a condition that takes place when generation of reactive oxygen species (ROS) exceed the antioxidant capacity of the cell. Several evidence suggest a key role for oxidative stress in RGC loss caused by glutamate-induced retinal damage (Luo et al., 2001; Nucci et al., 2005b; Tezel, 2006) and therefore free radical scavengers can be used to prevent cell death under excitotoxic conditions (Lipton and Rosenberg, 1994). Inhibition of fundamental functions in mitochondria leading to defective energy metabolism is one of the detrimental effects generated by free radical species (Patel et al., 1996; Duchen, 2000). Using high IOP-induced ischemia, our group reported that coenzyme Q10, an essential cofactor of the electron transport chain, afforded retinal neuroprotection after topical application (Nucci et al., 2007a; Russo et al., 2008b). Interestingly, using microdialysis technique we also observed that coenzyme Q10 is able to prevent vitreal glutamate increase minimizing RGC death (Nucci et al., 2007a). Overactivation of glutamate receptors leads to formation of the permeability transition pore (PTP) and, consequently, to RGC apoptotic death (see Kroemer and Reed, 2000). Interestingly, coenzyme Q10 has been shown to inhibit apoptosis by maintaining PTP in the closed conformation via a mechanism independent from free radical scavenging (Papucci et al., 2003). Therefore, it can be hypothesized that coenzyme Q10 acts on mitochondrial energy metabolism and this is reflected on EAAs function.

Interestingly, Lee et al. (2014) reported that a diet supplemented with coenzyme Q10 protects against excitotoxicity and oxidative stress damage in an experimental model of glaucoma in DBA/2J mice. In particular, coenzyme Q10 promotes RGC survival by modulating Bax and Bad protein expression and by preserving mitochondrial DNA content and mitochondrial transcription factor A/oxidative phosphorylation complex IV protein expression (Lee et al., 2014). These same authors also reported that brimonidine protects RGCs against excitotoxicity-induced oxidative stress in rat. Particularly, the α-2 adrenergic agonist preserved the expression of mitochondrial transcription factor A and oxidative phosphorylation complex in ischemic retina (Lee et al., 2012).

4.1.3. Cannabinoids

Experimental findings suggest that cannabinoids also may minimize excitotoxic RGC damage. Although, several studies have shown that topical administration of cannabinoids reduces IOP (Pate et al., 1995; Laine et al., 2001; Chien et al., 2003) by modulating both production and drainage of aqueous humor (Chien et al., 2003) by modulating both production and drainage of aqueous humor (Chien et al., 2003; Njie et al., 2006) a number of studies reported that cannabinoids exert neuroprotective effects in the eye against glutamate-induced excitotoxicity (Jarvinen et al., 2002; Crandall et al., 2007; Nucci et al., 2007b, 2008; Duncan et al., 2011), with potential implications for the treatment of glaucoma (Tomida et al., 2004; Yazulla, 2008). Interestingly, some studies suggested that inhibition of glutamate release represents a key mechanism involved in neuroprotection mediated by the cannabinoid system (Braida et al., 2000; Sinor et al., 2000; Marsicano et al., 2003; Gobira et al., 2015; Lin et al., 2015). In 2007, our group using an animal model of acute glaucoma reported that inhibition of fatty acid amide hydrolase (FAAH) or administration of metanandamide, a stable analogue of anandamide, minimize RGC loss caused by ischemia/reperfusion and that MK801, a noncompetitive NMDA receptors antagonist, controls anandamide degradation through FAAH (Nucci et al., 2007b). Accordingly, it is likely that excitotoxic stimuli may affect the metabolism of endocannabinoids in the mammalian retina. We also suggested that FAAH inhibitors like URB597 might become useful pharmacologic tools to counteract RGC damage (Nucci et al., 2007b). Consistent with these findings, recently, Slusar et al. (2013) reported that URB597 increases RGCs survival following optic nerve axotomy and this neuroprotective effect occurs primarily via activation of type 1 cannabinoid receptors (CB1). Accordingly, several studies suggested a key role for CB1 receptors activation in cannabinoid neuroprotection. In agreement, CB1-knockout mice have been reported to be more sensitive to inflammatory and excitotoxic insults than control animals (Pryce et al., 2003) and activation of CB1 receptors elicits inhibitory effects by reducing glutamate release (Howlett et al., 2004; Lin et al., 2015). Interestingly, Gobira et al. (2015) suggested that cannabidiol, a non-psychotomimetic constituent of Cannabis sativa, shows neuroprotection reducing glutamate release through activation of mTOR pathway. Cannabidiol and Δ9-tetrahydrocannabinol also have been shown to prevent retinal neurotoxicity by reducing the formation of NO after in vivo intravitreal injection of NMDA (El-Remessy et al., 2003). In addition, more recently, Duncan et al. (2011) reported that linoleoylethanolamine protects neurons in the RGC layer against glutamate excitotoxicity in ex-vivo retina cultures reducing apoptosis.

4.2. Endogenous pro-survival pathways and neuroprotection

It is conceivable that endogenous protective responses are activated, at least during the early stage of the disease, in order to counteract and balance the stressing milieu; accordingly, death of RGCs can be envisaged as the result of the failure/dysfunction of autoprotective responses.

The phosphoinositide-3 kinase (PI3K) pathway (Brazil and Hemmings, 2001) is physiologically activated by several neurotrophins, such as brain derived neurotrophic factor (BDNF), insulin like growth factor I (IGF-I), nerve growth factor (NGF) (Kaplan and Miller, 2000), turning on the protein kinase B (PKB), also known as Akt, a serine/threonin kinase endowed with pro-survival and anti-apoptotic effects (Franke et al., 2003).

Several studies have shown the activation of the PI3K/Akt pathway in response to glaucoma-related experimental insult like excitotoxicity (Manabe and Lipton, 2003; Nakazawa et al., 2005), ocular hypertension (Kanomori et al., 2004; Kim and Park, 2005; Levkovitch-Verbin et al., 2007), retinal ischemia induced by optic nerve clumping (Nakazawa et al., 2003) or transient elevation of IOP (Russo et al., 2008a). Activation of Akt is one of the mechanisms through which administration of neurotrophins, such as IGF-I, BDNF or erythropoietin (EPO), prevents RGC apoptosis following optic nerve axotomy (Klocker et al., 2000; Nakazawa et al., 2002; Weishaupt et al., 2004). Similarly, substances of natural origin like crocin, a pharmacologically active component of saffron (Crocus sativus L) or forskolin (7 beta-acetoxy-8,13-epoxy-1 alpha, 6 beta, 9 alpha-trihydroxy-labd-14-ene-11-one), the main active compound extracted from the roots of Coleus forskohlii, prevent RGC apoptosis induced by retinal ischemia/reperfusion by acting on the PI3K/Akt signaling pathway (Qi et al., 2013; Russo et al., 2015a).

The reported increase of RGC death observed in PI3K inhibitors-treated retinas following optic nerve clamping or retinal ischemia further support the neuroprotective role for the endogenous activation of this pathway (Nakazawa et al., 2003; Huang et al., 2008; Russo et al., 2008a).

It has been shown that the neuroprotection afforded by...
treatment with neurotrophic factors is potentiated by the simultaneous administration of substances with antioxidant activities. Indeed, association of BDNF with a non-specific free radical scavenger, N-tetra-butyl-(2-sulphophenyl)-nitro-triene (t-NAME), increased survival of RGCs in ocular hypertensive eyes (Ko et al., 2000). Furthermore, BDNF-mediated neuroprotection was potentiated by t-NAME, a NOS inhibitor, in axotomized RGCs (Klocker et al., 1998). Similarly, our group has recently shown that when forskolin is combined with homataurin and t-carnosine, substances endowed with antioxidant and neurmodulatory properties, respectively, produces a more pronounced neuroprotective effect on RGC survival following transient IOP increase and this is partly mediated by activation of the PI3K/Akt pathway (Russo et al., 2015a).

Autophagy is an evolutionarily conserved process by which eukaryotic cells regulate the turnover of long-lived proteins and cytoplasmic organelles and it gained recent attention for its involvement in the pathophysiology of several, including neurodegenerative, diseases (Cuervo et al., 2004; Glick et al., 2010). Most evidence suggest a neuroprotective role of this pathway that would help neurons to get rid of altered and damaged proteins and protein aggregates while degrading endogenous components in order to recycle the metabolic by-products (i.e. amino acids, fatty acids, nucleotides and others) for new synthesis. Autophagy is constantly active in each cell supporting homeostatic functions, but it can also act as adaptive catabolic process in response to several stimuli (Kourtis and Tavernarakis, 2009). mTOR is the main negative regulator of the process which is orchestrated by 36 different autophagy-related genes (Atg) coordinating the formation of a double membrane structure (autophagosome) and its fusion with lysosomes where the cargo is degraded (Levine and Klionsky, 2004; Nakatogawa et al., 2009).

Growing evidence supports the involvement of the autophagic process in the pathophysiology of glaucoma and several studies reported a dysregulation, either toward induction or inhibition, of the pathway (recently reviewed in Russo et al., 2013a, 2015b). Upregulation of Atg proteins were reported following optic nerve transection by Kim et al. (2008). Similarly, autophagosome accumulation was shown in the retina of GFP-LC3 mice subjected to optic nerve axotomy (Rodriguez-Muela et al., 2012). Accordingly, Ca+2+-dependent accumulation of LC3-positive autophagosomes was also detected in RGC axons following optic nerve crush (Knoferle et al., 2010). However, contradictory results were reported regarding the role attributed to autophagy induction following optic nerve injuries. Indeed, while the data reported by Rodriguez-Muela et al. (2012) showed increased RGC survival after treatment of axotomized mice with rapamycin, a mTOR inhibitor widely used to induce autophagy, Knoferle et al. (2010) reported that inhibition of the pathway by intravitreal injection of 3-methyladenine (3-MA) delayed the neurodegenerative process.

Downregulation of the autophagosome-associated protein LC3II and proteolytic cleavage of beclin-1, a protein essential in the initial step of the process, have been associated with RGC death induced by retinal ischemia/reperfusion in rats (Russo et al., 2011). However, in a similar experimental model, upregulation of LC3II and ultrastructural features of double and multi-membrane acidic vesicles (autophagosomes) were also reported (Piras et al., 2011; Wei et al., 2015).

Autophagy was induced in a chronic hypertensive glaucoma model induced by laser photocoagulation in primates (Deng et al., 2013) and increased number of autophagosomes and of autophagy related proteins, LC3II and beclin-1, were detected in soma and dendrites of RGCs from rats subjected to episcleral vein catarization (Park et al., 2012). In the latter study, pharmacological inhibition of autophagy by 3-MA increased cell survival in the ganglion cell layer suggesting a protective role for autophagy (Park et al., 2012). Accumulation of autophagic vacuoles and increased level of the autophagic substrate p62 were detected in unmyelinated axons suggesting an impairment of the process following laser-induced IOP elevation (Kitao et al., 2013). Under this experimental condition treatment with the autophagy inducer rapamycin exerted protective effects, while autophagy inhibition exacerbated axonal damage (Kitao et al., 2013). Vice versa, in the same glaucoma model induced by laser photocoagulation, Su et al. (2014) reported a significant reduction of RGC loss following treatment with rapamycin.

4.3. RGCs subtypes and neuroprotection

In a recent paper, Vidal-Sanz et al. (2015) described a new subtype of retinal RGC defined intrinsically photosensitive RGCs (ipRGCs). These cells, expressing photopigment melanopsin, detects light, behave like photoreceptors and are involved in several non-image-forming visual functions. In particular, they regulate the melatonin release, the pupillary control, and play a major role in synchronizing circadian rhythms to the 24-h light/dark cycle.

Interestingly, animal models of ocular hypertension (OHT) induced by laser-photocoagulation (Valiente-Soriano et al., 2015) indicated, although with a different pattern, a similar proportion of cellular death in the general population of RGCs (Bn3a+ RGCs) and the ipRGCs melanopsin-expressing type (m+ RGCs). Brn3a+ RGCs, in fact, showed a sectorial damage while m+ RGCs, revealed a diffuse pattern of loss. Moreover, the intravitreal injection of BDNF induced a different neuroprotective response indicating that Brn3a+ RGCs are amenable to BDNF while m+ RGCs are not.

Overall, this data shows that even in the same cellular population some subtypes may differently respond to neuroprotective molecules of well-known efficacy, suggesting how in the assessment of the effectiveness of these molecules is also important the evaluation of the target cellular type.

5. Conclusion

Glaucoma is still a leading cause of blindness in the world. As highlighted in the review numerous evidences indicate that the disease also involves the central areas of the visual system. There are also data indicating that glaucoma presents common aspects with other neurodegenerative or vascular diseases of the central nervous system. Altogether, these data emphasize the need to identify new therapeutic strategies based on neuroprotection. The results presented here confirm that numerous molecules have been shown to be effective in preventing neuronal damage in experimental models of glaucoma. However, to date, there are no sufficient clinical evidence confirming the efficacy of such molecules in patients with glaucoma.

Acknowledgements

Partial financial support from PRIN (Project protocol 20109MXHMR_008) and from University of Calabria (ex quota 60%) are gratefully acknowledged.

References


Y receptors activation protects rat retinal neural cells against necrotic and apoptotic cell death induced by glutamate. Cell Death Dis. 16 (4), e636.


Thouin, A., Grif


